Multiple sclerosis market to be worth $32.9bn in 2028

pharmafile | December 11, 2019 | News story | Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma 

The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 to $32.9 billion in 2028.

This is due to the launch of 11 new pipeline agents, providing more options and stimulating further competition.

This is according to GlobalData’s latest report: Multiple Sclerosis – Global Drug Forecast and Market Analysis to 2028. It also details how a further 14 late-stage drug products will launch in the seven major markets during, or shortly after, the forecast.

Alessio Brunello, Senior Pharma Analyst at GlobalData, said: “The launch of Mayzent in March 2019 and the potential launch of two other receptor inhibitors – ozanimod and ponesimod – will increase competition in the MS market and these new drugs will take patient share from the approved treatment – Novartis’ Gilenya.”

Brunello added: “The MS market is heading towards earlier and more aggressive therapies, with studies in the US questioning whether people with MS who are recently diagnosed should already go on with one of the monoclonal antibody therapies.”

MS drugs have a diverse line-up of upcoming drugs with 49 products in all stages of clinical development, with 25 in the-late stage pipeline. Many of these treatments focus on progressive MS. Currently there is a lack of focus on progressives MS subtypes, and patients with this version of the disease do not have many options.

Conor Kavanagh

Related Content


Biogen announces collaboration on novel MS treatment

Biogen and InnoCare Pharma have announced a license and collaboration agreement for orelabrutinib, an oral …

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

Latest content